AMLX
Amylyx·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AMLX
Amylyx Pharmaceuticals, Inc.
A biopharmaceutical company that developing treatment for neurodegenerative diseases
43 Thorndike St., Cambridge, Massachusetts 02141
--
Amylyx Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on January 10, 2014. The company is a clinical-stage pharmaceutical company with a mission to develop and advance new therapies for communities with unmet medical needs. The company has ongoing preclinical and clinical development programs in neurodegenerative and endocrine diseases. The company is advancing a pipeline in which it has matched investigational therapies to the diseases in which it believes these therapies can have the greatest impact, based on well-defined mechanistic principles, clear clinical outcomes and biomarkers, and rigorous preclinical data, independent of patterns.
Earnings Call
Q2/2025
Estimate EPS-0.45
Actual EPS-0.46
Estimate Revenue--
Actual Revenue0
Amylyx Pharmaceuticals' Q2 2025: Key Contradictions in PBH Patient Estimates, Trial Analysis, and Market Opportunities
Aug 07,2025 05:24
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
AMLX has released its 2025 Q3 earnings. EPS was reported at -0.37, versus the expected -0.43, beating expectations. The chart below visualizes how AMLX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
